InterVivo offers a carefully selected array of neuroscience models and experiments to help propel new drugs forward through the development track. Our efficacy models span across therapeutic domains including pain, epilepsy, obesity, addiction, Parkinson’s and Alzheimer’s Disease.
Our adaptable rodent operant platform, provides access to a superior set of sensitive and statistically powerful behavioural experiments to help clear a path forward for new drugs.
With the world’s largest aged laboratory beagle colony, we have the ability to study complex age-related disease development in a variety of phenotypic cohorts which surpasses the limited translatability of other animal models. We welcome and partner regularly with groups around the world to investigate new models and applications for our laboratory colonies.
There is a great need for better, safer and more effective anti-epileptic drugs (AEDs) that help prevent seizures and avoid unwanted side-effects. InterVivo provides a range of epilepsy models including acute and kindled seizures. This range of model types help detect and profile the anti-epileptic properties of new drugs, while offering the opportunity to benchmark new drugs against all known standard-of-care AEDs.LEARN MORE >
InterVivo is a leading provider of both rodent and canine models for investigating the effectiveness of drugs against obesity and metabolic dysregulation. A suite of models is available including genetically modified obese rats (Zucker fa/fa) and diet-induced models. Combined with our operant based tests we can also evaluate the effect of NCEs on motivation for food and potentially identify safety concerns or abuse liability of new drugs.LEARN MORE >
Neuropsychiatric drugs often have a higher risk profile due to unintended effects including potential abuse liability. InterVivo offers a range of rodent tests to identify potential liabilities and compare the behavioural effects of NCEs against known drugs of abuse, as well as identify the potential of an NCE to reduce a drug’s abuse profile. Studies include evaluation of locomotor stimulant effects or adaptive behavioural changes such as conditioned place preference or aversion. We also have access to IV self-administration apparatus allowing for operant based testing for a new drugs addictive potential.LEARN MORE >
To induce Parkinsonism in rodents for the identification and development of new therapies, we utilize the rotenone rat model. Our experience with protocols that offer dose-related, graded dopaminergic depletions and the ability to assess endpoints at the behavioural, biochemical and anatomical level, provides opportunities to study the effects of an NCE against these endpoints.LEARN MORE >
The neurodegeneration and progressive cognitive decline observed in Alzheimer’s disease is mirrored in our Aging Beagle model. The model provides the ability to study symptomatic and disease modifying effects of new drugs. Lead your NCE through early proof of concept to a characterised clinical candidate with our world-class expertise in preclinical research including cognitive assessment, in vivo imaging, and biomarker monitoring.LEARN MORE >
Neurological drugs need to clearly demonstrate symptomatic benefit in order to provide value. By studying progression of disease in aging animals, improvement of and protection from cognitive decline can be evaluated. Leveraging a naturally developing model of disease and sensitive neurological tests, we can translate early findings into clinical outcomes, and help speed development of new therapies.LEARN MORE >
InterVivo has developed a world-class rodent operant platform that allows testing of NCEs against discrete symptom clusters such as: Motivation, Motor Behaviour, Motor Impulsivity, Choice Impulsivity, Compulsive Behaviour, Drug Discrimination, Attention and Anxiety. The operant testing modality, which includes our standard operant and 5-choice chambers provides the sensitivity to detect subtle yet significant variations in behavioural response. InterVivo also regularly co-develops customized testing paradigms, providing additional opportunities for sponsors to fully develop the value of their emerging NCEs.LEARN MORE >